For the Q3 2026 reporting period (fiscal Q1 2027), The Marzetti Company is expected to report consensus revenue of $502.0 million and earnings per share of $1.37, while the stock currently trades at $109.74 compared to a $143.60 analyst target.
The central focus for investors is the recent Cyclospora outbreak, which management previously signaled would significantly pressure retail segment sales and potentially lower quarterly operating income by 15%.
Analysts are evaluating the performance of the newly acquired Bachan’s brand and its ability to drive long-term growth despite these temporary headwinds. Furthermore, shareholders are monitoring if record-high productivity gains can continue to bolster margins as the company navigates volume disruptions in its fresh-cut produce categories.